Croda International enhances its personal care portfolio with the aquisition of Solus Biotech.
This latest acquisition by the manufacturer of high-performance of ingredients will enhance the current synthetic ceramides portfolio delivered by Sederma, drawing on Solus’ existing biotech-derived ceramide and phospholipid technologies.
Located in South Korea, Solus will expand Croda’s Asian manufacturing capability and create a new biotechnology R&D hub in the region, working in synergy with Sederma’s R&D centre in LePerray, France.
Adding the exceptional knowledge and innovative ceramide portfolio of Solus significantly strengthens Croda’s beauty actives offering. The acquisition also boosts Croda’s total offering across its Personal Care portfolio, with Solus’ innovative phospholipids to be incorporated into the supplier’s skin care and hair care franchises, sitting together across other leading formulation and product platforms.
Exciting developments in ceramides portfolio
Representing the Sederma business, global business director, Luc Emprin shares his enthusiasm: “This is a very exciting opportunity for Croda. Our existing ceramides, currently from Sederma, will be complemented by these natural fermentation-derived ceramides, furthering our portfolio of high efficacy science-based ingredients. We are pleased to add Solus’ manufacturing site in South Korea to our operations, furthering our growth strategy for this key region. Innovation synergies between our different R&D labs will bring additional technical value and business opportunities for our customers all over the world.”
The strategic addition of Solus Biotech is in line with the company’s Purpose to use ‘Smart science to improve lives’ and supports the company’s ambition to be the most sustainable supplier of innovative ingredients.
Leave a Reply
You must be logged in to post a comment. Need an account? Register here.